Our bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Cancer immunotherapy has been revolutionized by targeting specific immune subsets within the tumor microenvironment, where T cells play a pivotal role. Gene-engineered T cell strategies and immune ...

Visiting Nassau County on Tuesday, Gov. Kathy Hochul announced plans for the New York BioGenesis Park, a $430 million, ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...